Innocan Pharma Corporation

Recent News

  • Richard Serbin, Former Johnson & Johnson's VP and a Leading Global Strategy Advisor in the Healthcare Industry, to Join Innocan Pharma's Scientific Advisory Committee

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 6, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Richard Serbin to its Advisory Committee. Richard Serbin will work closely with Innocan's leadership to address the emerging global Pharma opportunities, to expand Innocan's presence as part of its growth strategy, and to contribute from his extensive experience as Johnson & Johnson's Executive Vice President of Corporate Development, as former...

    2021-04-06 4:00 PM ET
  • Innocan Reports Q4 2020 Financial Results

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 1, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today its financial results and business highlights for the fourth quarter and year period ended December 31, 2020 and provide highlights and comments on these results. This news release should be read in conjunction with the Company's audited financial statements for this period (the "Financial Statements") and corresponding Management's Discussion and Analysis...

    2021-04-01 3:00 AM ET
  • Leading American Dermatologist Dr. Mitchell Kline to Join Innocan Pharma's Scientific Advisory Committee

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") is proud to announce the addition of Dr. Mitchell Kline to its Scientific Advisory Committee. Dr. Kline will serve as an active member of Innocan's R&D team, using his extensive experience in researching and treating different skin conditions, to further develop Innocan's derma cosmetic line. 

    2021-03-23 4:00 AM ET
  • Innocan Pharma Announces Proceeds of CDN $ 3.1M from the Exercise of Warrants Since January 1, 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 16, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since January 1, 2021, it has received proceeds of approximately CDN $3.1M as a result of the exercise of approximately 11.9 million previously issued common share purchase warrants (the "IPO Warrants") and certain broker warrants.Pursuant to the terms of the IPO Warrants, the Company's volume weighted average share price on the Canadian...

    2021-03-16 4:20 PM ET
  • Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment

    Herzlia, Israel and Calgary, Alberta--(Newsfile Corp. - March 10, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") filed an international patent application for a novel cannabis-based Anti-itch treatment. The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching associated with insect bites, rash, cuts, burns or by exposure to various allergens.

    2021-03-10 4:00 AM ET
  • Innocan Pharma Announces the Completion of its First Full-Scale Manufacturing Run in the US and the Launching of its US Commercial Online Platform

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 22, 2021) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan"), is pleased to announce the completion of its first full and large-scale commercial production of its SYNONY premium cosmetic line and Relief &Go OTC pain relief spray in the United States and the launch of its US Commercial Website.Innocan has successfully completed its first commercial manufacturing run in the US of 40,000 Units of its...

    2021-02-22 5:00 PM ET
  • Innocan Pharma Announces Proceeds of CDN $ 1.8M from the Exercise of Warrants Since December 1, 2020

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the "Company" or "Innocan") today announces that since December 1, 2020, it has received proceeds of approximately CDN $1.8M as a result of the exercise of approximately 7.6 Million previously issued common share purchase warrants and broker warrants. "The exercise of the warrants," states CEO Iris Bincovich, "Indicates that investors are confident in InnoCan Pharma". Bincovich adds that "following...

    2021-01-28 5:00 PM ET
  • Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - January 22, 2021) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the "Company" or "Innocan"), is pleased to announce today a successful manufacturing demonstration of liposome platform technology ("LPT") CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem. This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies...

    2021-01-22 3:00 AM ET